ActivX was an emerging biopharmaceutical company that discovered and developed highly selective, best in class, small molecule drugs for major unmet medical needs. ActivX used its unique technology to identify target and off-target activities of drug candidates in the protein kinase and protease families with a focus on hematology, oncology, metabolic and inflammatory diseases. Our core technology allows identification and development of highly selective drugs, lowering development risk.